Man Group PLC Chemo Centryx, Inc. Transaction History

Man Group PLC

$36 Billion
Q3 2024

Shares

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 14, 2022	BUY	$22.17 - $51.8 $16.6 Million - $38.8 Million	749,342 New	749,342 $38.7 Million
Q2 2022 Aug 15, 2022	SELL	$15.36 - $27.51 $435,548 - $780,073	-28,356 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$22.22 - $39.12 $630,070 - $1.11 Million	28,356 New	28,356 $711,000
Q2 2021 Aug 16, 2021	SELL	$9.59 - $50.88 $725,742 - $3.85 Million	-75,677 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$49.53 - $68.4 $1.61 Million - $2.22 Million	-32,490 Reduced 30.04%	75,677 $3.88 Million
Q4 2020 Feb 16, 2021	BUY	$47.25 - $65.16 $474,201 - $653,945	10,036 Added 10.23%	108,167 $6.7 Million
Q3 2020 Nov 16, 2020	BUY	$46.35 - $61.69 $371,727 - $494,753	8,020 Added 8.9%	98,131 $5.38 Million
Q2 2020 Aug 14, 2020	BUY	$38.58 - $65.07 $2.25 Million - $3.79 Million	58,224 Added 182.59%	90,111 $5.19 Million
Q1 2020 May 15, 2020	BUY	$32.73 - $50.78 $1.04 Million - $1.62 Million	31,887 New	31,887 $1.28 Million
Q4 2019 Feb 18, 2020	SELL	$6.81 - $39.55 $493,486 - $2.87 Million	-72,465 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$6.47 - $8.96 $318,938 - $441,683	-49,295 Reduced 40.49%	72,465 $491,000
Q2 2019 Aug 14, 2019	BUY	$8.31 - $14.85 $388,899 - $694,965	46,799 Added 62.43%	121,760 $1.13 Million
Q1 2019 May 15, 2019	BUY	$10.01 - $13.89 $750,359 - $1.04 Million	74,961 New	74,961 $1.04 Million
Q4 2018 Feb 14, 2019	SELL	$9.15 - $12.26 $185,186 - $248,130	-20,239 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$10.49 - $13.72 $212,307 - $277,679	20,239 New	20,239 $255,000

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.